Novo Nordisk’s trial of oral semaglutide meets primary endpoint

OASIS 1 compared the safety and efficacy of 50mg of semaglutide administered orally once a day against a placebo in 667 adults for 68 weeks.

Novo Nordisk said a superior weight loss of 15.1% had been observed in patients treated with semaglutide against a reduction of 2.4% in patients who were given the placebo.